SEMAGLUTIDE (Ozempic®) injection
Clinical Indication
GLP 1 analogue
Comments
Conditional on prescriber being competent to select appropriate patients.
First choice GLP-1 RA for T2DM new starts where BMI < 35 in line with NICE NG28
First choice GLP-1 RA for T2DM new starts where BMI > 35 – SC Semaglutide (Ozempic) or SC Tirzepatide (Mounjaro) in line with NICE NG28
Local guidance
Date of classification
March 2019
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.